Thrombopoietin Secretion by Human Ovarian Cancer Cells

Overview

Journal Int J Cell Biol

Publisher Wiley

Specialty Cell Biology

Date 2017 May 4

PMID 28465688

Citations 6

Authors

Samaher Besbes

Shahid Shah

Iman Al-Dybiat

Shahsoltan Mirshahi

Helene Helfer

Haythem Najah

Caroline Fourgeaud

Marc Pocard

Ibtissem Ghedira

Jeannette Soria

Massoud Mirshahi

Affiliations

Soon will be listed here.

Abstract

The thrombopoietin (TPO) gene expression in human ovary and cancer cells from patients with ovarian carcinomatosis, as well as several cancer cell lines including MDA-MB231 (breast cancer), K562 and HL60 (Leukemic cells), OVCAR-3NIH and SKOV-3 (ovarian cancer), was performed using RT PCR, real-time PCR, and gene sequencing. Human liver tissues are used as controls. The presence of TPO in the cells and its regulation by activated protein C were explored by flow cytometry. TPO content of cell extract as well as plasma of a patient with ovarian cancer was evaluated by ELISA. The functionality of TPO was performed in coculture on the basis of the viability of a TPO-dependent cell line (Ba/F3), MTT assay, and Annexin-V labeling. As in liver, ovarian tissues and all cancer cells lines except the MDA-MB231 express the three TPO-1 (full length TPO), TPO-2 (12 bp deletion), and TPO-3 (116 pb deletion) variants. Primary ovarian cancer cells as well as cancer cell lines produce TPO. The thrombopoietin production by OVCAR-3 increased when cells are stimulated by aPC. OVCAR-3 cell's supernatant can replace exogenous TPO and inhibited TPO-dependent cell line (Ba/F3) apoptosis. The thrombopoietin produced by tumor may have a direct effect on thrombocytosis/thrombosis occurrence in patients with ovarian cancer.

Citing Articles

Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment.

Chen Y, Zhou J, Liu Z, Wu T, Li S, Zhang Y J Exp Clin Cancer Res. 2023; 42(1):277.

PMID: 37872588 PMC: 10591353. DOI: 10.1186/s13046-023-02856-1.

Targeted Delivery of Sunitinib by MUC-1 Aptamer-Capped Magnetic Mesoporous Silica Nanoparticles.

Torabi M, Aghanejad A, Savadi P, Barzegari A, Omidi Y, Barar J Molecules. 2023; 28(1).

PMID: 36615606 PMC: 9824472. DOI: 10.3390/molecules28010411.

Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues.

Braun A, Anders H, Gudermann T, Mammadova-Bach E Front Oncol. 2021; 11:665534.

PMID: 34322381 PMC: 8311658. DOI: 10.3389/fonc.2021.665534.

Platelets, Thrombocytosis, and Ovarian Cancer Prognosis: Surveying the Landscape of the Literature.

Hufnagel D, Cozzi G, Crispens M, Beeghly-Fadiel A Int J Mol Sci. 2020; 21(21).

PMID: 33142915 PMC: 7663176. DOI: 10.3390/ijms21218169.

Platelets and Metastasis: New Implications of an Old Interplay.

Lucotti S, Muschel R Front Oncol. 2020; 10:1350.

PMID: 33042789 PMC: 7530207. DOI: 10.3389/fonc.2020.01350.

References

Marcucci R, Romano M . Thrombopoietin and its splicing variants: structure and functions in thrombopoiesis and beyond. Biochim Biophys Acta. 2008; 1782(7-8):427-32. DOI: 10.1016/j.bbadis.2008.03.007. View

Furuhashi M, Miyabe Y, Oda H . A case of thrombopoietin-producing ovarian carcinoma confirmed by immunohistochemistry. Gynecol Oncol. 1999; 74(2):278-81. DOI: 10.1006/gyno.1999.5428. View

Kiontke S, Langemeyer L, Kuhlee A, Schuback S, Raunser S, Ungermann C . Architecture and mechanism of the late endosomal Rab7-like Ypt7 guanine nucleotide exchange factor complex Mon1-Ccz1. Nat Commun. 2017; 8:14034. PMC: 5216073. DOI: 10.1038/ncomms14034. View

Sohma Y, Akahori H, Seki N, Hori T, Ogami K, Kato T . Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett. 1994; 353(1):57-61. DOI: 10.1016/0014-5793(94)01008-0. View

de Sauvage F, Hass P, Spencer S, Malloy B, Gurney A, Spencer S . Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994; 369(6481):533-8. DOI: 10.1038/369533a0. View

Jones Jr D, Ashby M, Vadhan-Raj S, Somlo G, Champlin R, Gajewski J . Recombinant human thrombopoietin clinical development. Stem Cells. 2000; 16 Suppl 2:199-206. DOI: 10.1002/stem.5530160723. View

Boucharaba A, Serre C, Gres S, Saulnier-Blache J, Bordet J, Guglielmi J . Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004; 114(12):1714-25. PMC: 535068. DOI: 10.1172/JCI22123. View

Schmittgen T, Livak K . Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. DOI: 10.1038/nprot.2008.73. View

Foster D, Sprecher C, Grant F, Kramer J, Kuijper J, Holly R . Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci U S A. 1994; 91(26):13023-7. PMC: 45573. DOI: 10.1073/pnas.91.26.13023. View

10.

Sungaran R, Markovic B, Chong B . Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood. 1997; 89(1):101-7. View

11.

Marty C, Saint-Martin C, Pecquet C, Grosjean S, Saliba J, Mouton C . Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood. 2014; 123(9):1372-83. DOI: 10.1182/blood-2013-05-504555. View

12.

Bambace N, Holmes C . The platelet contribution to cancer progression. J Thromb Haemost. 2010; 9(2):237-49. DOI: 10.1111/j.1538-7836.2010.04131.x. View

13.

Azzazene D, Al Thawadi H, Al Farsi H, Besbes S, Geyl C, Mirshahi S . Plasma endothelial protein C receptor influences innate immune response in ovarian cancer by decreasing the population of natural killer and TH17 helper cells. Int J Oncol. 2013; 43(4):1011-8. PMC: 3829768. DOI: 10.3892/ijo.2013.2021. View

14.

Althawadi H, AlFarsi H, Besbes S, Mirshahi S, Ducros E, Rafii A . Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment. Oncol Rep. 2015; 34(2):603-9. PMC: 4487670. DOI: 10.3892/or.2015.4061. View

15.

Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K . An improved colorimetric assay for interleukin 2. J Immunol Methods. 1986; 93(2):157-65. DOI: 10.1016/0022-1759(86)90183-3. View

16.

Estrov Z, Talpaz M, Mavligit G, Pazdur R, Harris D, Greenberg S . Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med. 1995; 98(6):551-8. DOI: 10.1016/s0002-9343(99)80013-8. View

17.

Bick R . Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost. 1992; 18(4):353-72. DOI: 10.1055/s-2007-1002575. View

18.

Wojtukiewicz M, Sierko E, Kisiel W . The role of hemostatic system inhibitors in malignancy. Semin Thromb Hemost. 2007; 33(7):621-42. DOI: 10.1055/s-2007-991530. View

19.

Stone R, Nick A, McNeish I, Balkwill F, Han H, Bottsford-Miller J . Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012; 366(7):610-8. PMC: 3296780. DOI: 10.1056/NEJMoa1110352. View

20.

Khorana A, Francis C, Culakova E, Lyman G . Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005; 104(12):2822-9. DOI: 10.1002/cncr.21496. View